

SECRET

06 MAR

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Organization		Biotechnology Industry Organization	
2. Address <input type="checkbox"/> Check if different than previously reported			
1225 Eye St., NW		Suite 400	
City	Washington	State	DC
		Zip Code	20005
		Country	USA
3. Principal place of business (if different than line 2)			
City		State	
		Zip Code	
		Country	
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Mr.	Tom DiLenge	(202) 962-6671	tdilenge@bio.org
7. Client Name <input checked="" type="checkbox"/> Self		5. Senate ID #	
Biotechnology Industry Organization		6245-12	
		6. House ID #	
		32505000	

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report ☒

10. Check if this is a Termination Report ☐ ⇨ Termination Date _____ 11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>2,840,000</u></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options:</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Revenue Code</p>
--	--

Form Com

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

0000072713




VD m m m

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code ACC - Accounting (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

HR 913 Broad Based Stock Option Plan Transparency Act
HR 3385 To Amend the Internal Revenue Code of 1986 to Clarify the Treatment of Incentive Stock Options and Employee Stock Purchase Plans

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives White House
US Senate IRS
US Dept. of Treasury
SEC

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Morrie	Ruffin		
W. Charles	Lucas		
Libby	Solon		
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations


Bo
Z

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code AGR - Agriculture (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

Proposed policy re: Adventitious Presence
Proposed policy re: Regulation of Transgenic animals
HR 1563, S 767 National Food and Agriculture Science Act of 2005
HR 2744 Agriculture Appropriations

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives	Dept. of State
US Senate	USTR
FDA	EPA
USDA	

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Sean	Darragh		
Michael	Phillips		
Val	Giddings		
Barbara	Glenn		
Jim	Eichhorst		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

Pro
2

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

Appropriations Bills (HR 2744 Agriculture, HR 2361 Interior, HR 2862 Commerce, Justice, State, HR 2863 Defense, HR 2360 Homeland Security)
Supplemental Appropriations Budget
HR 2791, PTO Fee Bill

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives	OMB	Dept. of Energy
US Senate	OSTP	Dept. of Commerce
FDA	USDA	PTO
HHS	EPA	

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Libby	Solon		
Val	Giddings		
Michael	Phillips		
Brent	Erickson		
Michael	Werner		
Lila	Feisee		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations



Boo
7

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue >

HR 2791 PTO Fee bill
 HR 2862 Commerce, State, Justice Appropriations
 HR 5299 Patent Quality Assistance Act of 2004
 Human Cloning Patent Amendment
 HR 2795 Patent Reform Act of 2005

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives	Commerce Office of Science Policy
US Senate	Dept. of State
PTO	HHS
NIH	USTR

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Lila	Feisee		
W. Charles	Lucas		
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Bo
7

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code DEF - Defense (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

S. 3 Protecting America in the War on Terror Act of 2005
S. 975 Project BioShield II Act of 2005
HR 2863 Defense Appropriations
Biobased Purchasing Policy
Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives
US Senate
Dept. of Defense
DHS

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Brent	Erickson		
Sean	Darragh		
Val	Giddings		
W. Charles	Lucas		
Amit	Sachdev		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations



Box
2

Client Name **Biotechnology Industry Organization**

15. General issue area code ENG - Energy/Nuclear (one per page)

HR 6, S 10 Energy Policy Act of 2005
 HR 1608, S 650 Fuels Security Act
 S 1210 National Security & Bioenergy Investment Act of 2005
 Bioenergy Legislation
 Funding for research & development of advanced biotech and energy and chemical production
 Agriculture policy

US House of Representatives	Dept. of Defense
US Senate	Dept. of Agriculture
Dept. of Commerce	White House
Dept. of Energy	

[illegible]

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

Boo
2

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area ENG

16. Specific lobbying issues (continued from previous page)

Biobased purchasing policy

88888872728

Box
7

172000721




Pool
2

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code HOM - Homeland Security (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

S. 3 Protecting America in the War on Terror Act of 2005
 S. 975 Project BioShield II Act of 2005
 S. 969 Attacking Viral Influenza Across Nations Act of 2005
 S. 1437 Bioterrorism and Pandemic preparedness Act of 2005
 Untitled Burr biodefense bill
 Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives FDA
 US Senate White House
 Dept. of Defense
 USDA

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Brent	Erickson		
W. Charles	Lucas		
Amit	Sachdev		
Libby	Solon		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations



Page
7

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

HR 810, S 471 Stem Cell Research Enhancement Act of 2004
 HR 1650 Stem Cell Research Investment Act
 HR 596, S681 Cord Blood Stem Cell Act
 HR 2520 Stem Cell Therapeutic & Research Act
 HR 182, S876 Human Cloning Ban & Stem Cell Research Protection Act
 S 317 Bone Marrow & Cord Blood Therapy & Research Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives	FDA	White House
US Senate	Dept. of State	
HHS	CDC	
NIH	NIST	

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Amit	Sachdev		
Michael	Werner		
Sara	Radcliffe		
W. Charles	Lucas		
Lila	Feisee		
Libby	Solon		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization**ADDENDUM for General Lobbying Issue Area** MED

16. Specific lobbying issues (continued from previous page)

HR 1227, S306 Genetic Information Nondiscrimination Act of 2005
HR 3010 Labor HHS Appropriations
Clinical Trial Information Disclosure
Bayh-Dole March-in rights
NIH Conflict of Interest
FDA Review Practices
FDA Drug Safety
Cell, Gene and Tissue Therapy
Pharmacogenomics
PDUFA Implementation

0000072724

Boo

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

HR 563 Prescription Drug Affordability Act
 HR 1626 Medicare Prescription Drug Improvement Act
 HR 752, S873 Medicare Prescription Drug Savings and Choice Act of 2005
 MMA Implementation
 Medicaid
 Off-Label studies

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives OMB
 US Senate White House
 HHS
 CMS

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Alan	Eisenberg		Policy Advisor, Rep. James Greenwood
Amit	Sachdev		
Jayson	Slotnik		
Libby	Solon		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations



Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area MMM

16. Specific lobbying issues (continued from previous page)

Reconciliation

30000072726

Add page to continue specific issues description for this iss.

Pool

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue >

HR 700, S 334 Pharmaceutical Market Access & Drug Safety Act of 2005
 HR 752, S 873 Medicare Prescription Drug Savings and Choice Act of 2005
 HR 1626 Medicare Prescription Drug Improvement Act
 FDA Issues including: Post Market Surveillance, Clinical trials, drug reviews, drug manufacturing, and counterfeiting
 Prescription Drug User Fee Act (Implementation)

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives OMB
 US Senate White House
 HHS
 FDA

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
W. Charles	Lucas		
Amit	Sachdev		
Libby	Solon		
Sara	Radcliffe		
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

Boo

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI - Science/Technology (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

HR 2943, S 1263 Save America's Biotechnology Innovative Research Act
HR 250 Manufacturing Technology Competitiveness Act of 2005
HR 6, S 10 Energy Policy Act of 2005

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives
US Senate
SBA
White House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
W. Charles	Lucas		
Morrie	Ruffin		
Brent	Erickson		
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Libby	Solon		
Lila	Feisee		
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None


Boo

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code SMB - Small Business (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

HR 2943, S 1263 Save America's Biotechnology Innovative Research Act
Sec. 382 issues

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives
US Senate
SBA
White House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
W. Charles	Lucas		
Morrie	Ruffin		
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger
Dave	Boyer		Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Libby	Solon		
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

1300

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code TAX - Taxation/Internal Revenue Code (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

HR 913 Broad Based stock option Plan Transparency Act
 HR 3385 To Amend the Internal Revenue Code of 1986 to Clarify the Treatment of Incentive Stock
 Options and Employee Stock Purchase plans
 HR 1736, S 627 Investment in America Act (R&D) tax credit
 Sec. 382 Issues

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives White House
 US Senate IRS
 Dept. of Treasury
 SEC

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Morrie	Ruffin		
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger
Libby	Solon		
Susie	Ahn		Senior Legislative Assistant for Rep. Mike Honda

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

A handwritten signature or scribble consisting of several loops and a trailing line.

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

HR 3045 CAFTA Implementation Bill
WTO Case on Moratorium in EU
WTO Case on Traceability and Labeling
General WTO issues
Trade Related IP Agreements
Harmonization Efforts

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

US House of Representatives	Dept. of State	USTR
US Senate	USDA	
White House	FDA	
EPA	USPTO	

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Brent	Del Monte		Counsel, House Energy and Commerce Committee
Val	Giddings		
Michael	Phillips		
Brent	Erickson		
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger
Lila	Feisee		
Libby	Solon		
Sean	Darragh		

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Add a page for a different

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

1300

Registrant Name Biotechnology Industry Organization

Client Name Biotechnology Industry Organization

ADDENDUM for General Lobbying Issue Area TRD

16. Specific lobbying issues (continued from previous page)

TRIPS

Add page to continue specific issues description for this is

0000072732

POD
7

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address

City	State	Zip Code	Country

21. Client new principal place of business (if different than line 20)

City	State	Zip Code	Country

22. New general description of client's business or activities

LOBBYIST UPDATE23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix

1

3

2

4

ISSUE UPDATE

Find the code to select below.

24. General lobbying issues that **no longer** pertain**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State Country
	Address	City
	C/S/Z	State

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Owner percent client
	Street Address			
	City State/Province Country	City		
		State Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

1

3

5

2

4

6

Add a page for more updates

Printed Name and Title Brent Del Monte, Vice President, Federal Government Relations

[Handwritten signature]



SECRETARY OF I
06 MAR -3 PM

BIOTECHNOLOGY
INDUSTRY
ORGANIZATION

February 24, 2006

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

To Whom it May Concern:

Please find enclosed an amended version of the Biotechnology Industry Organization's Lobbying Report for the mid-year filing period of 2005. At the time of our original filing for that period, we misinterpreted the "Covered Official Position" field to mean the lobbyist's current position at our organization, rather than his or her previous position within the federal government, if applicable. We have corrected that error in this amendment. Additionally, our previous contact, Ms. Heather Chaney, has departed and been replaced by Mr. Tom DiLenge, and we have amended our report to reflect this personnel change. This amended report contains no changes beyond those outlined above.

Please do not hesitate to contact me if you require any other information.

Sincerely,

Peter Jaffe
Assistant to Mr. DiLenge

0000072734

202-962-9200

FAX 202-962-9201

<http://www.bio.org>